Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KI-1125
- Development stage
- Preclinical
- Lead developer
- Kuhnil Pharmaceutical
- Modality
- Small Molecules
01
Overview
**KI-1125** is a preclinical small-molecule cardiovascular drug candidate developed by Kuhnil Pharma for hyperlipidemia and hypertension. Kuhnil Pharma's pipeline identifies the program and these intended indications, but does not publicly disclose its molecular target, pharmacological mechanism, chemical structure, route of administration, or formulation. ([kuhnil.com](https://www.kuhnil.com/en/rnd5.php))
- Other names
- KI 1125KI1125KI-1125
Beyond the preview
Go deeper on KI-1125.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KI-1125.